Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088006 | PMC |
| http://dx.doi.org/10.21037/tlcr-2023-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prospects of the therapeutic approaches of ketogenic diet on the clinical outcomes of cancer: A scoping review.
Bull Cancer
September 2025
Clinical Pharmacy Department, Faculty of Pharmacy, Istinye University, Istanbul, Türkiye.
The scientific community has become more enthusiastic about ketogenic diet (KD) to improve the outcomes in medical conditions, including cancer by exploiting the reprogramed metabolism of cancer cells, making the diet a promising candidate as an adjuvant cancer therapy. From this perspective, the aim of this study was to provide a broad overview covering the therapeutic effects, evaluating the clinical evidence of clinical studies underlying the implementation of the KD in the context of cancer treatment and prognosis. A scoping literature search between the years 1990 and 2023 was carried out by using PRISMA guidelines and searching through different databases of the clinical studies supporting the effectiveness and benefits of KD in various carcinomas that could provide findings of evidence on the prognosis and clinical outcomes of cancer treatment.
View Article and Find Full Text PDFEnhanced recovery after surgery and long-term oncologic outcomes: post-hoc analysis of the POWER study.
Rev Esp Anestesiol Reanim (Engl Ed)
September 2025
Department of Anaesthesia and Critical Care, Hospital Universitario Infanta Leonor, Madrid, Spain; Universidad Complutense de Madrid, Madrid, Spain; Spanish Perioperative Audit and Research Network, Zaragoza, Spain.
Introduction/objectives: Colorectal cancer (CRC) remains a leading cause of cancer-related mortality. While Enhanced Recovery After Surgery (ERAS) programs optimize perioperative care, their effect on oncologic prognosis requires further validation. This study evaluates ERAS adherence and five-year survival through a post-hoc analysis of the POWER Study.
View Article and Find Full Text PDFLong-Term Results of a Phase II Prospective Clinical Trial of Single-Fraction, High-Gradient Adjuvant Partial Breast Irradiation in Early-Stage, Hormone Positive Breast Cancer.
Int J Radiat Oncol Biol Phys
September 2025
Department of Radiation Oncology, Washington University School of Medicine in Saint Louis, Saint Louis, MO, USA. Electronic address:
Purpose: This study evaluates the long-term outcomes of single-fraction, high-gradient partial breast irradiation (BreaStBRT) as a post-operative treatment in patients with early-stage, hormone-positive breast cancer. It aims to assess acute and late treatment-related toxicity, cosmesis, patient-reported quality of life (QoL), and oncologic outcomes.
Materials And Methods: Single-institution, single-arm, phase II prospective trial included post-menopausal women ≥50 years old with early-stage, hormone-positive breast cancer treated with breast-conserving therapy (BCT) followed by BreaStBRT.
Pde5a deficiency prevents diet-induced obesity via adipose cAMP-PKA activation enhancing fat browning.
Mol Metab
September 2025
Department of Experimental Medicine, Sapienza University of Rome, Rome, 00161, Italy. Electronic address:
Cyclic nucleotides are critical regulators of adaptive thermogenesis and adipogenesis, with their intracellular levels finely tuned by phosphodiesterases. Phosphodiesterase type 5 (PDE5A) modulates cyclic guanosine monophosphate (cGMP) levels in adipocytes. While PDE5A inhibition has shown promise in patients with diabetes, its role in metabolism remains unclear.
View Article and Find Full Text PDFThe role of adjuvant radiotherapy in relation to tumor size for bone-invasive pT4aN0 oral squamous cell carcinoma - A retrospective observational matched cohort study.
Oral Oncol
September 2025
Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Oral and Maxillofacial Surgery, Augustenburger Platz 1, 13353 Berlin, Germany.
Objective: Oral squamous cell carcinoma (OSCC) with bone invasion are staged as pT4a, potentially upstaging smaller tumors. This study aimed to evaluate the oncological benefit of postoperative radiotherapy (PORT) in pT4aN0 OSCC with respect to tumor size and without other risk factors.
Methods: This retrospective matched cohort study included pT4aN0 OSCC patients with bone invasion treated surgically (R0) between 2010 and 2022.